SAN DIEGO, April 22, 2022 (GLOBE NEWSWIRE) -- The Class: Shareholder rights law firm Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) securities between May 7, 2021 and February 26, 2022, for violates of the Securities Exchange Act of 1934. Aurinia is a biopharmaceutical company that develops and commercializes therapies to treat diseases with unmet medical need in Japan and the People's Republic of China. The Company's only product is LUPKYNIS, which it offers for the treatment of adult patients with active lupus nephritis.
If you would like more information about Aurinia Pharmaceuticals Inc.'s misconduct, click here.
What is this Case About: Aurinia Pharmaceuticals Inc. Misstated the Financial Impact of its Drug LUPKYNIS
According to the complaint, throughout the class period, defendants failed to disclose that Aurinia was experiencing declining revenues and that the 2022 sales outlook for LUPKYNIS would fall short of expectations.
On February 28, 2022, Aurinia announced its financial results for the full quarter and full year ended December 31, 2021, including a year-over-year revenue decline and lower than expected sales outlook for 2022. On this news, Aurinia's stock fell $3.94 per share, or 24.26%, to close at $12.30 per share on February 28, 2022.
Next Steps: If you acquired shares of Aurinia Pharmaceuticals Inc. (AUPH) between May 7, 2021 and February 26, 2022, you have until June 14, 2022, to ask the court to appoint you lead plaintiff for the class. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. You do not have to participate in the case to be eligible for a recovery.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Contact us to learn more:
Aaron Dumas
(800) 350-6003
adumas@robbinsllp.com
Shareholder Information Form
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against Aurinia Pharmaceuticals Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.
| Contact: Aaron Dumas Robbins LLP 5040 Shoreham Place San Diego, CA 92122 adumas@robbinsllp.com (800) 350-6003 www.robbinsllp.com |
